Ideaya Sets Registrational Trial Strategy for IDE849 for Neuroendocrine Carcinomas
Ideaya plans a 90-patient extension cohort and two Phase 3 trials to seek accelerated and full approval for IDE849.
6 Articles
6 Articles
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpointRandomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval,…
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas - PressReach
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval, with OS as the primary endpoint IDE849 has demonstrated a 52.6% ORR (10/19), median … Continue reading "IDEAYA Biosciences Announces Successful US FDA Type C Me…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium









